The latest generation of state-of-the-art cancer treatment is now available to Northern Nevada patients, only at Carson Tahoe Health. Michelle Joy, chief operating Officer, announced Monday that Carson Tahoe Health is the first in the region to offer the new Microwave Ablation technology by NeuWave Medical. Using the skinniest incision probes and the highest powered microwave system on the market, this industry-leading technique destroys tumors in sensitive tissues including the liver, kidneys and lungs.
As a minimally invasive outpatient procedure, the revolutionary MWA system treats even the smallest lesions or nodules in the most challenging locations. Additionally, it can be performed with conscious sedation or general anesthesia in less than 40 minutes; and the average patient makes a full recovery in just two to three days.
Dr. Sandra Althaus, Interventional Radiologist at Carson Tahoe Health and the first physician in Northern Nevada to use MWA, added it, “provides us the ability to perform a customized ablation based on the patient’s unique needs, whether utilizing a multi-probe approach for large tumors, or a ‘precision’ probe for small, focal ablations.”
Prior to MWA, patients would typically be required to undergo a radiofrequency ablation procedure. While the radiofrequency procedure would take up to four hours, the MWA can be performed in less than 40 minutes. Following a MWA procedure, patients can make a full recovery in just three or four days, rather than three or four weeks after a radiofrequency ablation.
“At Carson Tahoe, we are committed to serving our community with the latest technological advancements in a tranquil healing environment,” Joy said. “We feel very fortunate to offer the MWA ablation system — the same technology utilized at our nation’s top academic and research institutions — right here in Northern Nevada.”
To learn more about innovative treatments at Carson Tahoe Health, visit: www.CarsonTahoe.com
Comments
Use the comment form below to begin a discussion about this content.
Sign in to comment